We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New AI System Performs As Well As Radiologists in Detecting Prostate Cancer

By HospiMedica International staff writers
Posted on 24 Apr 2019
Researchers from the University of California {(UCLA), Los Angeles, CA, USA} have developed a new artificial intelligence (AI) system to help radiologists improve their ability to diagnose prostate cancer. More...
The system, called FocalNet, helps identify and predict the aggressiveness of the disease evaluating magnetic resonance imaging (MRI) scans with almost the same level of accuracy as experienced radiologists.

Typically, radiologists use MRI to detect and assess the aggressiveness of malignant prostate tumors. However, this requires practicing on thousands of scans to learn how to accurately determine whether a tumor is cancerous or benign and to accurately estimate the grade of the cancer. Additionally, many hospitals lack the resources to implement the highly specialized training required for detecting cancer from MRIs.

FocalNet is an artificial neural network that can help radiologists improve their ability to diagnose prostate cancer by using an algorithm comprising over one million trainable variables. The UCLA researchers trained the system by making it analyze MRI scans of 417 men with prostate cancer. The scans were fed into the system so that it could learn to assess and classify tumors in a consistent way and have it compare the results to the actual pathology specimen. The researchers tested FocalNet and found it to be 80.5% accurate in reading MRIs, as compared to radiologists having at least 10 years of experience who were 83.9% accurate. This suggests that an AI system could save time and potentially provide diagnostic guidance to less-experienced radiologists.

Related Links:
University of California Los Angeles



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.